Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently become a major concern for a broad spectrum of health care providers. Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM) are at center stage, as T2DM appears to worsen the course of NAFLD and the liver disease makes diabetes management more challenging. However, the nature of this relationship remains incompletely understood. Although the increasing prevalence of NAFLD is frequently attributed to the epidemic of obesity and is often oversimplified as the "hepatic manifestation of the metabolic syndrome," it is a much more complex disease process that may also be observed in nonobese individuals and in patients without clinical manifestations of the metabolic syndrome. It carries both metabolic and liver-specific complications that make its approach unique among medical conditions. Diabetes appears to promote the development of nonalcoholic steatohepatitis (NASH), the more severe form of the disease, and increases the risk of cirrhosis and hepatocellular carcinoma. Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and few pharmacological agents with proven efficacy. However, recent advances in diagnosis and treatment, combined with the risk of serious consequences from inaction, call for health care providers to be more proactive in the managem…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD, and in particular NASH, is also associated with an increased risk of cardiovascular complications; therefore, people with NAFLD should have their cardiovascular risk factors assessed and managed to minimize this risk (303).”
In the citing paper
“Rat studies have shown that removal of visceral adipose tissue increases insulin sensitivity while delaying T2D (75), and prevents metabolic syndrome and NAFLD (76).”
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Research works printed but not linked: 1
- Sanyal, 2016, Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study (Abstract), Hepatology, 64, 1118A
Cited by
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationStefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Self-citationMetabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Masarone, M., Rosato, V., Dallio, M., Gravina, A. G., Aglitti, A., Loguercio, C., Federico, A., & Persico, M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9547613 · Cited by 648
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 624
Taylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N., & Lean, M. E. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.003 · Cited by 450
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324
“Rat studies have shown that removal of visceral adipose tissue increases insulin sensitivity while delaying T2D (75), and prevents metabolic syndrome and NAFLD (76).”
BackgroundSunny, N. E., Bril, F., & Cusi, K. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.11.006 · Cited by 319
Self-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationPlasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Niu, L., Geyer, P. E., Wewer Albrechtsen, N. J., Gluud, L. L., Santos, A., Doll, S., Treit, P. V., Holst, J. J., Knop, F. K., Vilsbøll, T., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188793 · Cited by 285
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Hepatic Insulin Clearance: Mechanism and Physiology
Najjar, S. M., & Perdomo, G. (2019) · Physiology · doi:10.1152/physiol.00048.2018 · Cited by 246
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Self-citationBril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199
Self-citationBril, F., McPhaul, M. J., Caulfield, M. P., Clark, V. C., Soldevilla-Pico, C., Firpi-Morell, R. J., Lai, J., Shiffman, D., Rowland, C. M., & Cusi, K. (2020) · Diabetes Care · doi:10.2337/dc19-1071 · Cited by 179
Self-citationZhang, C., Deng, J., Liu, D., Tuo, X., Xiao, L., Lai, B., Yao, Q., Liu, J., Yang, H., & Wang, N. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14482 · Cited by 177
Chyau, C.-C., Wang, H.-F., Zhang, W.-J., Chen, C.-C., Huang, S.-H., Chang, C.-C., & Peng, R. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010360 · Cited by 173
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R., & Sanyal, A. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 168
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 168
Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism
Ardestani, A., Lupse, B., & Maedler, K. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.04.006 · Cited by 160
Esquejo, R. M., Salatto, C. T., Delmore, J., Albuquerque, B., Reyes, A., Shi, Y., Moccia, R., Cokorinos, E., Peloquin, M., Monetti, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.009 · Cited by 147
Barb, D., Repetto, E. M., Stokes, M. E., Shankar, S. S., & Cusi, K. (2021) · Obesity · doi:10.1002/oby.23263 · Cited by 146
Self-citationTakeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 145
Drożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 122
Kinoshita, T., Shimoda, M., Nakashima, K., Fushimi, Y., Hirata, Y., Tanabe, A., Tatsumi, F., Hirukawa, H., Sanada, J., Kohara, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13279 · Cited by 121
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Rhee, E. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.226 · Cited by 119
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Caturano, A., Acierno, C., Nevola, R., Pafundi, P. C., Galiero, R., Rinaldi, L., Salvatore, T., Adinolfi, L. E., & Sasso, F. C. (2021) · Processes · doi:10.3390/pr9010135 · Cited by 104
Handelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 119
Eslam, M., Ahmed, A., Després, J., Jha, V., Halford, J. C. G., Chieh, J. T. W., Harris, D. C. H., Nangaku, M., Colagiuri, S., Targher, G., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00132-1 · Cited by 112
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship
Muzica, C. M., Sfarti, C. V., Trifan, A. V., Zenovia, S., Cuciureanu, T., Năstasă, R., Huiban, L., Cojocariu, C., Sîngeap, A.-M., Gîrleanu, I., et al. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/6638306 · Cited by 114
Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease
Hadi, H. E., Vincenzo, A. D., Vettor, R., & Rossato, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092215 · Cited by 107
Guo, W., Lü, J., Qin, P., Li, X., Zhu, W., Wu, J., Xu, N., & Zhang, Q. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01393-6 · Cited by 103
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Bril, F., McPhaul, M. J., Caulfield, M. P., Castille, J. M., Poynard, T., Soldevila‐Pico, C., Clark, V., Firpi-Morell, R. J., Lai, J., & Cusi, K. J. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000864 · Cited by 97
Self-citationCusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Self-citationKantartzis, K., Fritsche, L., Bombrich, M., Machann, J., Schick, F., Staiger, H., Kunz, I., Schoop, R., Lehn‐Stefan, A., Heni, M., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13268 · Cited by 87
The metabolic basis of nonalcoholic steatohepatitis
Chakravarthy, M. V., & Neuschwander‐Tetri, B. A. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.112 · Cited by 87
Diabetes and cirrhosis: Current concepts on diagnosis and management
Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 93
Self-citationPeleman, C., Francque, S., & Berghe, T. V. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105088 · Cited by 99
Peter, A., Kovarova, M., Staiger, H., Machann, J., Schick, F., Königsrainer, A., Königsrainer, I., Schleicher, E., Fritsche, A., Häring, H.-U., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00262.2017 · Cited by 82
Lin, Q., Huang, Z., Cai, G., Fan, X., Yan, X., Liu, Z., Zhao, Z., Li, J., Li, J. X., Shi, H., et al. (2020) · Hepatology · doi:10.1002/hep.31568 · Cited by 83
Stote, K. S., Wilson, M. M., Hallenbeck, D., Thomas, K., Rourke, J. M., Sweeney, M. I., Gottschall‐Pass, K. T., & Gosmanov, A. R. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa030 · Cited by 92
Park, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01483-y · Cited by 83
Chen, M., Guo, W.-L., Li, Q.-Y., Xu, J.-X., Cao, Y.-J., Liu, B., Yu, X.-D., Rao, P.-F., Ni, L., & Lv, X.-C. (2020) · Food & Function · doi:10.1039/c9fo03003d · Cited by 77
Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 86
Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD
Worm, N. (2020) · Nutrients · doi:10.3390/nu12051316 · Cited by 83
Dajani, A. I., & Popovic, B. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i21.5235 · Cited by 79
Barbosa, J. V., & Lai, M. (2021) · Hepatology Communications · doi:10.1002/hep4.1618 · Cited by 68
Chooi, Y. C., Zhang, Q. A., Magkos, F., Ng, M., Michael, N., Wu, X., Volchanskaya, V. S. B., Lai, X., Wanjaya, E. R., Elejalde, U., et al. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.11.013 · Cited by 69
Musolino, V., Gliozzi, M., Bombardelli, E., Nucera, S., Carresi, C., Maiuolo, J., Mollace, R., Paone, S., Bosco, F., Scarano, F., et al. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.02.004 · Cited by 74
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 67
Self-citationEstablished and emerging factors affecting the progression of nonalcoholic fatty liver disease
Kechagias, S., Nasr, P., Blomdahl, J., & Ekstedt, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154183 · Cited by 68
Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
Ge, C., Tan, J., Dai, X., Kuang, Q., Zhong, S., Lai, L., Yi, C., Sun, Y., Luo, J., Zhang, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33493-5 · Cited by 67
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Lv, X., Dong, Y., Hu, L., Lu, F., Zhou, C., & Qin, S. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.163 · Cited by 65
Lifestyle interventions for non-alcoholic fatty liver disease
Ahmed, I. A., Mikail, M. A., Mustafa, M. R., Ibrahim, M., & Othman, R. (2019) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2018.12.016 · Cited by 68
Jian, C., Ding, X., Wu, R., Tong, B., Zhao, L., Lv, H., Meng, X., Liu, Y., Ren, B., Li, J., et al. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05596 · Cited by 68
Kurinami, N., Sugiyama, S., Yoshida, A., Hieshima, K., Miyamoto, F., Kajiwara, K., Jinnouch, K., Jinnouchi, T., & Jinnouchi, H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.017 · Cited by 62
Li, B., Cheng, Y., Yu, S., Zang, L., Yin, Y., Liu, J., Zhang, L., & Mu, Y. (2019) · Stem Cells International · doi:10.1155/2019/8628027 · Cited by 58
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Budd, J., & Cusi, K. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.007 · Cited by 60
Self-citationRole of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61
Self-citationShannon, C. E., Ragavan, M., Palavicini, J. P., Fourcaudot, M. J., Bakewell, T. M., Valdez, I., Ayala, I., Jin, E. S., Madesh, M., Han, X., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101154 · Cited by 68
Dludla, P. V., Orlando, P., Silvestri, S., Marcheggiani, F., Cirilli, I., Nyambuya, T. M., Mxinwa, V., Mokgalaboni, K., Nkambule, B. B., Johnson, R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093247 · Cited by 57
Hu, W., Gong, W., Yang, F., Cheng, R., Zhang, G., Gan, L., Zhu, Y., Qin, W., Gao, Y., Li, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113937 · Cited by 66
Xiao, J., Ng, C. H., Chan, K. E., Fu, C., Tay, P., Yong, J. N., Lim, W. H., Tan, D. J. H., Syn, N., Wong, Z. Y., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.006 · Cited by 56
Bril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.018 · Cited by 55
Self-citationArrese, M., Barrera, F., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 54
Shao, S., Chang, K., Lin, S.-J., Chien, R., Hung, M., Chan, Y., Yang, Y. K., & Lai, E. C. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0990-2 · Cited by 62
Dhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Self-citationNonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 59
Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
Castillo-Núñez, Y., Almeda‐Valdés, P., González-Gálvez, G., & Arechavaleta-Granell, M. D. R. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01542-6 · Cited by 59
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 59
Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care · doi:10.2337/dc18-2578 · Cited by 52
Self-citationMetabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Self-citationCariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
Cusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Self-citationBril, F., Millán, L., Kalavalapalli, S., McPhaul, M. J., Caulfield, M. P., Martinez‐Arranz, I., Alonso, C., Ortiz Betes, P., Mato, J. M., & Cusi, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13285 · Cited by 50
Self-citationIshiba, H., Sumida, Y., Seko, Y., Tanaka, S., Yoneda, M., Hyogo, H., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1637 · Cited by 56
Nonalcoholic Fatty Liver Disease
Isaacs, S. D. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.06.007 · Cited by 52
Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
Parry, S. A., & Hodson, L. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01281-6 · Cited by 55
Zou, Z., Wong, V. W., & Fan, J. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12871 · Cited by 53
Kaneto, H., Obata, A., Kimura, T., Shimoda, M., Kinoshita, T., Matsuoka, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063062 · Cited by 50
Seo, D. H., Suh, Y. J., Cho, Y., Ahn, S. H., Seo, S., Hong, S., Lee, Y., Choi, Y. J., Lee, E. J., & Kim, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0130 · Cited by 54
Ying, X., Rongjiong, Z., Kahaer, M., Chunhui, J., & Wulasihan, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1088187 · Cited by 47
Xu, Z., Hu, W., Wang, B., Xu, T., Wang, J., & Wei, D. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.7.619 · Cited by 50
Franch‐Nadal, J., Caballería, L., Mata‐Cases, M., Mauricio, D., Giráldez‐García, C., Mancera, J., Goday, A., Mundet, X., Regidor, E., & for the PREDAPS Study Group (2018) · PLoS ONE · doi:10.1371/journal.pone.0198327 · Cited by 51
Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma
Raza, S., Rajak, S., Anjum, B., & Sinha, R. A. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2019.014 · Cited by 54
Bian, H., Zhu, X., Xia, M., Yan, H., Chang, X., Hu, X., Pan, B., Guo, W., Li, X., & Gao, X. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0342 · Cited by 47
NAFLD: Challenges and opportunities to address the public health problem in Latin America
Arab, J. P., Díaz, L. A., Dirchwolf, M., Mark, H. E., Lazarus, J. V., Vaughan, E. C., Méndez‐Sánchez, N., de Oliveira, C. P. M. S., Gadano, A. C., & Arrese, M. A. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100359 · Cited by 50
Lee, P. C. H., Gu, Y., Yeung, M. Y., Fong, C. H. Y., Woo, Y. C., Chow, W. S., Tan, K., & Lam, K. S. L. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0355-3 · Cited by 44
Hong, L., Zahradka, P. C., Cordero-Monroy, L., Wright, B., & Taylor, C. G. (2019) · Nutrients · doi:10.3390/nu11040917 · Cited by 45
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
Basu, R., Noureddin, M., & Clark, J. M. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.04.005 · Cited by 50
Souto, K. P., Meinhardt, N. G., Ramos, M. J., Kulczynski, J. M. U., Stein, A. T., & Damin, D. C. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.09.527 · Cited by 59
Pagès, M. A. I., Moura‐Ramos, M., Araújo, S., Macedo, M. P., Ribeiro, R. T., Ó, D. D., Ramalho‐Santos, J., & Azul, A. M. (2020) · BMC Public Health · doi:10.1186/s12889-020-09249-5 · Cited by 51
NAFLD and autoimmune hepatitis: Do not judge a book by its cover
Dalekos, G. Ν., Gatselis, N., Zachou, K., & Koukoulis, G. Κ. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.02.001 · Cited by 49
Asbaghi, O., Naeini, F., Ashtary‐Larky, D., Kaviani, M., Kelishadi, M. R., Eslampour, E., Moradi, S., Mirzadeh, E., Clark, C. C. T., & Naeini, A. A. (2021) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2021.102755 · Cited by 44
Metadata
- Authors
- Bril, F., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Cusi, Kenneth
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-02-13
- Volume
- 40
- Issue
- 3
- Pages
- 419-430
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2589426226
- Cited by
- 341
- References
- 123
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 28 · 2023: 38 · 2022: 41 · 2021: 43 · 2020: 61 · 2019: 41 · 2018: 36 · 2017: 17
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, nonalcoholic steatohepatitis, metabolic syndrome, obesity, liver cirrhosis, hepatocellular carcinoma, NASH diagnosis, NASH treatment, disease natural history
- MeSH terms
- Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Humans, Hyperglycemia, Life Style, Liver Neoplasms, Obesity, Risk Factors, Prevalence, Randomized Controlled Trials as Topic, Metabolic Syndrome, Dyslipidemias, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.